Pfizer announced today that PF-05280586, the company’s proposed biosimilar to reference rituximab (Rituxan, MabThera), has been shown to be equivalent to the reference in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden follicular lymphoma.
Pfizer announced today that PF-05280586, the company’s proposed biosimilar to reference rituximab (Rituxan, MabThera), has been shown to be equivalent to the reference in overall response rate (ORR) for the first-line treatment of patients with CD20-positive, low tumor burden follicular lymphoma.
The positive top-line results were reported from the phase 3 REFLECTIONS B3281006 study, a randomized, double-blind clinical trial evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-05280586 versus the EU-approved MabThera.
REFLECTIONS B3281006 had an estimated enrollment of 394 adult participants and began in September 2014. It is expected to be completed later in 2018. The primary endpoint, ORR, is defined according to the revised response criteria for malignant lymphoma (time frame, week 26). Secondary outcome measures include time to treatment failure, progression-free survival, complete remission rate, duration of response, overall survival, incidence of anti-drug antibodies, and safety associated with immune response.
“These results reinforce the potential of our proposed rituximab biosimilar in providing a safe and effective treatment option for patients,” said Amrit Ray, MD, global president, Pfizer Essential Health Research and Development. “We are delivering on our commitment to advancing high-quality medicines for the millions of patients with cancer around the world today and in the future,” added Ray.
Pfizer has also investigated the proposed biosimilar for inflammatory indications. An earlier phase 1 clinical trial of PF-05280586 demonstrated pharmacokinetic similarity to US-licensed Rituxan and MabThera in 220 patients with active rheumatoid arthritis (RA) with inadequate response to 1 or more anti—tumor necrosis factor (anti-TNF) therapies. The researchers reported comparable pharmacodynamic responses as well as safety and immunogenicity profiles.
Another clinical trial of PF-05280586 in 214 patients with RA who had an inadequate response to anti-TNF drugs found no clinically meaningful differences in Disease Activity Score in 28 Joints (DAS28) or American College of Rheumatology (ACR) improvement criteria between the proposed biosimilar and the 2 reference drugs.
The complete results of the REFLECTIONS B3281006 trial will be submitted for presentation at a future medical conference or publication in a summary format, according to Pfizer.
Pfizer has 7 distinct biosimilar molecules in mid- to late-stage development, with 3 of these in oncology, as well as several others in early-stage development.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.